LUPIN LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,660 INR | 0.00% |
|
+3.11% | +25.46% |
| 10:36am | Lupin Gets Six Observations from US FDA After Somerset Unit Inspection | MT |
| 13/05 | Lupin Relaunches Mirabegron ER Tablets in US | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 200B 2.4B | Sales 2025 * | 217B 2.6B | Capitalization | 757B 9.09B |
|---|---|---|---|---|---|
| Net income 2024 | 19.14B 230M | Net income 2025 * | 23.97B 288M | EV / Sales 2024 | 3.68 x |
| Net Debt 2024 * | 24.9B 299M | Net Debt 2025 * | 8.41B 101M | EV / Sales 2025 * | 3.53 x |
| P/E ratio 2024 |
38.6
x | P/E ratio 2025 * |
31.6
x | Employees | 20,933 |
| Yield 2024 * |
0.43% | Yield 2025 * |
0.5% | Free-Float | 52.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lupin Limited
More recommendations
More press releases
More news
| 1 week | +3.11% | ||
| Current month | +0.88% | ||
| 1 month | +7.30% | ||
| 3 months | +4.56% | ||
| 6 months | +38.76% | ||
| Current year | +25.46% |
1 week
1 605.55
1 693.50
1 month
1 559.051 697.80
Current year
1 332.101 703.80
1 year
766.051 703.80
3 years
583.051 703.80
5 years
505.001 703.80
10 years
505.002 127.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/97/01 | |
Johnny Mikell
PSD | President | - | - |
| Director of Finance/CFO | 59 | 13/07/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 27/15/27 | |
Mark McDade
BRD | Director/Board Member | 69 | 28/21/28 |
| Director/Board Member | 50 | 01/96/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.38% | 6 M€ | +6.07% | - | |
| 0.12% | 11 M€ | +8.03% | ||
| 0.04% | 454 M€ | +9.82% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 1,660 | +0.45% | 3,093 |
| 17/24/17 | 1,652 | -0.56% | 17,891 |
| 16/24/16 | 1,662 | +1.38% | 47,617 |
| 15/24/15 | 1,639 | +0.17% | 10,851 |
| 14/24/14 | 1,636 | -3.05% | 45,301 |
Delayed Quote Bombay S.E., May 18, 2024 at 12:30 pm IST
More quotes
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas:
- design and production of generic and brand-name formulations;
- production of active pharmaceutical ingredients.
At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil.
Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
HOLD
Number of Analysts
35
Last Close Price
1,660
INR
Average target price
1,567
INR
Spread / Average Target
-5.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.46% | 9.08B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +13.81% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- LUPIN Stock
